Ascendis Pharma A/S (NASDAQ:ASND) Issues Quarterly Earnings Results

Key Points

• Earnings beat but revenue missed: Ascendis reported EPS of $0.31 versus the $0.21 consensus (+$0.10) while quarterly revenue of $285.45M trailed the $361.87M estimate.
• FDA approval and strong clinical readouts: The FDA approved YUVIWEL (TransCon CNP) for achondroplasia with early U.S. uptake of over 60 children and an EU decision expected in Q4 2026, and Phase II data for the TransCon CNP+TransCon hGH combo showed substantially greater Week‑52 efficacy versus monotherapy, potentially reducing the need for invasive limb/spine surgeries.
• Strategic pullback from oncology: Management discontinued internal development of TransCon IL‑2 β/γ despite encouraging Phase I/II signals, signaling a shift away from in‑house oncology programs and potential lost upside for that asset.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) released its earnings results on Thursday. The biotechnology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.10, FiscalAI reports. The business had revenue of $285.45 million for the quarter, compared to the consensus estimate of $361.87 million.

Here are the key takeaways from Ascendis Pharma A/S's conference call:

• FDA approval of a third TransCon product (YUVIWEL/TransCon CNP) for achondroplasia, with early U.S. uptake of more than 60 children prescribed within weeks and plans for selected international early access and an EU decision expected in Q4 2026.
• Q1 revenue totaled €247M (company cited ~€197M from its lead rare‑endocrine product and €44M from SKYTROFA), with operating profit €25M (10% margin), non‑IFRS net profit €18M, €573M cash on hand, a completed Nasdaq direct listing, redemption of convertible notes, and an agreed PRV sale for $187.5M.
• The Phase II COACH data for the TransCon CNP + TransCon hGH combination showed substantially greater Week‑52 efficacy versus monotherapy (height Z‑score, limb alignment, spinal canal and arm‑span improvements), which management says could reduce or eliminate the need for invasive limb/spine surgeries.
• Management decided to discontinue internal oncology development of TransCon IL‑2 β/γ despite encouraging Phase I/II signals, signaling a strategic pullback from oncology and potential loss of internal upside for that program.

Ascendis Pharma A/S Stock Up 4.3%

Shares of NASDAQ:ASND traded up $10.24 during trading on Thursday, hitting $246.14. 1,434,107 shares of the company were exchanged, compared to its average volume of 811,197. The business's 50 day moving average is $231.54 and its 200-day moving average is $218.99. The company has a market capitalization of $15.35 billion, a P/E ratio of -55.94 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $150.89 and a 1-year high of $250.74.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter worth $26,000. Arax Advisory Partners raised its position in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 104 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company's stock worth $46,000 after buying an additional 113 shares during the period. GW&K Investment Management LLC lifted its holdings in Ascendis Pharma A/S by 75.2% during the 4th quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company's stock worth $48,000 after buying an additional 97 shares during the period. Finally, Quadrant Capital Group LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $74,000.

Analyst Ratings Changes

Several research firms have weighed in on ASND. Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 20th. Morgan Stanley restated an "overweight" rating and set a $256.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. TD Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research note on Wednesday, March 4th. Finally, Wedbush restated an "outperform" rating and set a $273.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $291.56.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.